Browse Studies — Arctuva

Phase 1

Pilot Study of Scaling Busulfan Dose to Body Surface Area in Children Undergoing Hematopoietic Stem Cell Transplantation

The goal of this pilot study is to determine if scaling the first busulfan dose to Body Surface Area (BSA) in children with a BSA ≥0.5 m2 and using a BSA-bande…

Busulfan Pharmacokinetic AnalysisBusulfan DosingHematopoietic Stem Cell Transplant (HSCT)+2 more

Estimated

~$10 – $6,250

Children's Hospital of PhiladelphiaNCT07792369

Phase 2

Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients With Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) With Documented Viral Infections With PIV, hMPV or RSV

The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity …

Hematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)

Estimated

~$10 – $8,750

Pulmotect, Inc.NCT06665100

TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Ea…

Hematopoietic Stem Cell Transplant (HSCT)Diffuse Alveolar HemorrhageThrombotic Microangiopathies+2 more

Estimated

~$10 – $675

Children's Hospital Medical Center, CincinnatiNCT04098445

Phase 2

A Randomized, Placebo-Controlled Phase 2 Study of IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia…

IDH1 MutationAcute Myeloid Leukemia (AML)Hematopoietic Stem Cell Transplant (HSCT)

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06707493